Krina K. Patel, MD, MSc, discusses mitigating CAR T-cell therapy–related cytokine release syndrome in multiple myeloma.
Krina K. Patel, MD, MSc, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses mitigating CAR T-cell therapy–related cytokine release syndrome (CRS) in multiple myeloma.
Toxicity can be a limiting factor with CAR T-cell therapy in hematologic malignancies, Patel says. In lymphoma, key toxicities associated with CAR T-cell therapy include CRS and neurotoxicity; however, in multiple myeloma, CRS is the main toxicity to be aware of, Patel explains.
CRS often presents as grade 1 fever that responds to acetaminophen. Moreover, fevers are a good sign that the CAR T-cell therapy is working rather than indicative of a serious toxicity, such as sepsis, Patel explains.
However, in cases of higher-grade fevers that are accompanied by hypoxia or hypotension, tocilizumab (Actemra) can be considered, Patel says. Many patients with COVID-19 were treated with tocilizumab, which led to a shortage of the agent for patients with multiple myeloma receiving CAR T-cell therapy. As such, other options to treat CRS were utilized, including dexamethasone and IL-6 inhibitors like siltuximab (Sylvant), which elicited rapid responses, Patel concludes.
Dr Pal Previews ASCO 2024 Data in Renal Cell Carcinoma
Prospective Data Reveal Most Young Survivors of Breast Cancer Could Successfully Give Birth
HPV Vaccinations Associated With Lower Rates of HPV-Caused Cancers in Patients Under 40 Years of Age
AI Virtual Navigation May Reengage Patients to Undergo Missed Colonoscopies
2 Commerce Drive
Cranbury, NJ 08512